Guardant Health Inc

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Guardant Health reports robust Q1 earnings, eyes growth opportunities

Guardant Health's Q1 2023 earnings call showcased strong financial performance, advancements in screening technology, and a focus on operational efficiency. The company's revenue growth, successful Medicare reimbursement, and strategic guidance raise optimism for future growth. Challenges lie in managing expenses and commercial investments post-FDA approval.

Guardant Health reports robust Q2 results and eyes international expansion

Guardant Health's Q2 performance reflects strong revenue growth and test volume increase, with a focus on achieving cash flow breakeven.
The company's strengths lie in expanding payer coverage, advancing Shield blood tests, and seeing growth in the MRD market.
Challenges include legal expenses, low lung cancer screening rates, and managing cash burn, while opportunities exist in Japan market expansion and EMR integration.
Overall, Guardant Health is poised for growth with a strategic focus on innovation, market expansion, and financial sustainability.

Guardant Health reports strong Q3 performance, eyes international expansion

Guardant Health's Q3 2023 showcased robust revenue growth and strong test volume performance, particularly in Precision Oncology and Guardant360.
The company's focus on innovation, payer coverage breakthroughs, and international expansion presents significant growth opportunities.
While Shield V2 faces challenges in AA detection, progress on FDA approval and sales strategy post-approval are key areas of focus.
Overall, Guardant Health's strategic investments and product advancements position it well for continued growth and market leadership.

Guardant Health reports robust revenue growth and strategic advancements

Guardant Health's strong financial performance, focus on key strengths, and management of challenges position the company for continued growth
Opportunities in revenue growth, product upgrades, and market expansion present avenues for further success
Strategic initiatives in therapy selection, MRD, and screening underscore Guardant Health's commitment to innovation and market leadership

Guardant Health excels in Q2 2024 with FDA-approved Shield test

Guardant Health's Q2 2024 performance showcased strong revenue growth, driven by the success of the Shield blood test and Guardant360. While facing challenges in cash flow, the company remains optimistic about future opportunities in the diagnostic testing market.

Guardant Health reports robust Q3 earnings, eyes international expansion

Guardant Health's Q3 2024 earnings call highlighted strong revenue growth, exceeding expectations in key segments. The company raised its full-year revenue guidance and showcased improvements in free cash flow. Shield blood test and Reveal revenue are expected to drive future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.

Edwards Lifesciences

Intuitive Surgical

Boston Scientific

Novocure

Intuitive Surgical, Edwards Lifesciences, Boston Scientific, Novocure and Guardant Health are top medical stocks that may thrive as coronavirus cases fall.

Intuitive Surgical, Edwards Lifesciences Lead Five Top Stocks To Watch As Coronavirus Cases Fall, Elective Procedures Rise

Fastly

Novavax

You don't need a huge initial investment with massive growth opportunities from these stocks.

Investing $3,000 in These 3 Stocks Could Make You a Fortune Over the Next Decade

Advanced Micro Devices

If you won't need that $1,200 to pay your immediate bills, why not use it to bolster your long-term financial plan?

Optimistic That You'll Get a Second Stimulus Check? Plan to Invest It in These 3 Stocks

Guardant Health on Monday announced that the U.S. Food and Drug Administration granted emergency use authorization for its Covid-19 test.

Guardant Health Coronavirus Test Gets Emergency OK; GH Stock Nears Buy Point

COVID-19 diagnostic expands testing supply, protects the continuity of essential cancer work at Guardant Health, and helps with reopening at Delaware State University COVID-19 diagnostic expands testing supply, protects the continuity of essential cancer work at Guardant Health, and helps with reopening at Delaware State University

Guardant Health Receives FDA Emergency Use Authorization for its Guardant-19 Next Generation Sequencing-Based COVID-19 Test

REDWOOD CITY, Calif., Aug.  10, 2020  (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the following investor virtual conferences.

Guardant Health to Participate in Upcoming August Investor Conferences

Guardant Health, Inc. (GH) CEO Helmy Eltoukhy on Q2 2020 - Earnings Call Transcript

SINGAPORE, Aug. 7, 2020 /PRNewswire/ -- The U.S.

First liquid biopsy to receive FDA Approval for comprehensive tumor mutation profiling across all solid cancers, Guardant Health's Guardant360® CDx, advancing precision oncology in Asia, Middle East and Africa.

Now FDA approved, the Guardant360 CDx delivers critical genomic information to oncologists from a simple blood draw Now FDA approved, the Guardant360 CDx delivers critical genomic information to oncologists from a simple blood draw

Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers

The liquid biopsy company beat revenue estimates in Q2, but its bottom line fell short of expectations.

What's Behind Guardant Health's Mixed Q2 Results

Q2 2020 Revenue Increase of 23% Over Prior Year Period

Guardant Health Reports Second Quarter 2020 Financial Results

Selective Estrogen Receptor Degrader in Phase III Trial For Use in Resistant ER-Positive Breast Cancer Selective Estrogen Receptor Degrader in Phase III Trial For Use in Resistant ER-Positive Breast Cancer

Guardant Health Announces Collaboration with Radius Health to Develop Liquid Biopsy Companion Diagnostic for Elacestrant

Livongo Health Inc

These winning stocks should deliver huge returns over the next few years.

$10,000 Invested in These Growth Stocks Could Make You a Fortune

Is  (GH) Outperforming Other Medical Stocks This Year?

Is Guardant Health (GH) Outperforming Other Medical Stocks This Year?

REDWOOD CITY, Calif., July  21, 2020  (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the second quarter 2020 after market close on Thursday, August 6, 2020. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Guardant Health Announces Webcast of Second Quarter Financial Results on August 6, 2020

Alteryx

Block

They're growing fast and have fantastic long-term prospects.

Got $5,000? 3 Brilliant Stocks to Buy Right Now

A public offering of common stock pushed the stock lower, but strengthened the company's balance sheet.

Here's Why Guardant Health Dropped 10.2% in June

REDWOOD CITY, Calif., July  08, 2020  (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) today announced a strategic collaboration with Janssen Biotech, Inc. (Janssen) to pursue regulatory approval and commercialization of the Guardant360® CDx as a companion diagnostic for amivantamab, an investigational EGFR-MET bispecific antibody being studied in the treatment of non-small cell lung cancer (NSCLC). The agreement covers the United States, Canada, Japan, and Europe.

Guardant Health Announces Collaboration with Janssen to Develop Liquid Biopsy Companion Diagnostic

Amgen

Anthem

Bristol-Myers

Iovance Biotherapeutics

IQVIA Hlds

Medtronic

Veeva Systems

West Pharmaceutical Services

Acceleron Pharma

The pandemic has put the health care industry under a global spotlight.

10 Stocks to Invest in the Health Care Revolution

Illumina

Which stock wins in a matchup between these two healthcare stocks?

Better Buy: Illumina vs. Guardant Health

Represents a large-scale liquid biopsy dataset of advanced cancer patients Represents a large-scale liquid biopsy dataset of advanced cancer patients

Guardant Health Launches Real-World Clinical-Genomic Platform to Accelerate Precision Oncology Drug Development

Results from a small study will need to be validated by an ongoing study of 10,000 patients.

Guardant Health's Blood Cancer Test Detects Early-Stage Colon Cancer

Results from a new patient cohort consistent with previously reported data Results from a new patient cohort consistent with previously reported data

Guardant Health Presents Data at AACR Virtual Annual Meeting II Showing Liquid Biopsy Highly Accurate in Detecting Early-Stage Colorectal Cancer

REDWOOD CITY, Calif., June  16, 2020  (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has appointed Vijaya Gadde to serve on its Board of Directors.

Guardant Health Appoints Vijaya Gadde to its Board of Directors

Trade Desk

Any time is a great time to buy these three stocks.

News for Guardant Health Inc Stock (GH)